- Home
- ICU vs IMNN Comparison
ICU vs IMNN Comparison
Compare ICU & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- IMNN
- Stock Information
- Founded
- ICU 2018
- IMNN 1982
- Country
- ICU United States
- IMNN United States
- Employees
- ICU N/A
- IMNN N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- IMNN Health Care
- Exchange
- ICU Nasdaq
- IMNN Nasdaq
- Market Cap
- ICU 15.9M
- IMNN 12.9M
- IPO Year
- ICU N/A
- IMNN 1985
- Fundamental
- Price
- ICU $0.57
- IMNN $4.56
- Analyst Decision
- ICU
- IMNN Buy
- Analyst Count
- ICU 0
- IMNN 2
- Target Price
- ICU N/A
- IMNN $182.61
- AVG Volume (30 Days)
- ICU 1.7M
- IMNN 85.7K
- Earning Date
- ICU 11-13-2025
- IMNN 11-05-2025
- Dividend Yield
- ICU N/A
- IMNN N/A
- EPS Growth
- ICU N/A
- IMNN N/A
- EPS
- ICU N/A
- IMNN N/A
- Revenue
- ICU $766,000.00
- IMNN N/A
- Revenue This Year
- ICU $820.00
- IMNN N/A
- Revenue Next Year
- ICU $63.37
- IMNN N/A
- P/E Ratio
- ICU N/A
- IMNN N/A
- Revenue Growth
- ICU N/A
- IMNN N/A
- 52 Week Low
- ICU $0.31
- IMNN $4.45
- 52 Week High
- ICU $3.57
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- ICU 39.98
- IMNN 34.11
- Support Level
- ICU $0.60
- IMNN $4.66
- Resistance Level
- ICU $0.65
- IMNN $4.90
- Average True Range (ATR)
- ICU 0.05
- IMNN 0.32
- MACD
- ICU 0.00
- IMNN -0.03
- Stochastic Oscillator
- ICU 26.62
- IMNN 11.70
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).